Novo Nordisk’s Steep Decline: A Deep Dive into the Pharmaceutical Giant’s Challenges
Published on 11/18/2025 at 15:30 | Redaktion boerse-global.de
The Danish pharmaceutical firm Novo Nordisk, which held the title of Europe’s most valuable corporation just a year ago, is confronting a severe downturn. Propelled by the initial excitement surrounding its weight-loss injection Wegovy, the company’s fortunes have dramatically reversed. Since the start of the year, its stock has plummeted by more than 44 percent, reaching its lowest valuation since early 2024. This collapse points to issues far more profound than a temporary market correction, raising critical questions about the company’s future trajectory.
The full scope of Novo Nordisk’s difficulties was laid bare in its third-quarter 2025 report, released on November 5. While the net profit of $3.1 billion met analyst projections, Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
